Wed 23rd Apr 14, 18:52
Thursday will be another big day in capital markets in London. In particular, traders will be braced for the latest first quarter earnings figures out from drugs giant AstraZeneca.
Search news for stories that mention a company:
Show only the stories that interest you with news filter.
US stocks were still trading lower on Wednesday afternoon on the back of weaker-than-expected economic data and rising tensions in Ukraine. 1 hour ago
FTSE closes down 7.02 points at 6,674.74; Focus turns to Apple and Facebook earnings; UK public sector net borrowing falls 4 hours ago
A round-up of the biggest director deals today so far. 5 hours ago
Shares in oil and gas developer Aminex tanked on Wednesday after the firm posted a loss for 2013 of 17.3m dollars. 5 hours ago
Shares in renewable energy provider Drax lost more than 13 per cent of their value on Wednesday, hit by the group's announcement that one of its power station units was no longer deemed eligible by the UK government for an investment contract. 5 hours ago
AIM-listed Porta Communications has acquired a majority stake in financial PR firm Redleaf Polhill. 5 hours ago
Disclaimer: This news feed is provided by Digital Look Ltd. BullBearings Ltd do not necessarily share the views expressed within the stories. The stories are for general information purposes only and not a solicitation or personal reccomendation to deal. BullBearings Ltd accepts no liability or responsibility for any of the content contained in the information provided by Digital Look Ltd.
In this, the first of a series of four articles, I will explain some forex misconceptions are, and outline the feature that is the real “holy grail” of the market. In the following three parts, I will show how a robust trading strategy can be built that will give the new or aspiring trading an edge with an overwhelming probability of profitability over the long run.
In order to begin our journey, it helps to begin with an allegorical story, in order to demonstrate the nature and challenge of the struggle of trading.
Those who have followed me for some years will know I am a fan of seasonality and as I have explained in previous updates, financial markets do not go up or down evenly throughout the year in a nice orderly straight line; that would be far too easy.
If we invested $10,000 in the Dow Jones on 1st November and and then taken our money out on April 30st from 1950 to date we would now have over $950,000. We would have been out of the market May until end of October each year missing a few crashes in the process.
The USD/CHF pair fell during the session on Friday, but did so in a relatively tame manner, leading me to believe there are still opportunities for short-selling.
After all, we have seen for strong selloffs as far as daily candles are concerned, and then have finally see the market settle down for the Friday session.
Cloud computing services provider Nasstar (NASA) has been transformed by its acquisition of rival e-know.net. The integration of the operations is already far advanced and the business should be profitable this year.
e-know.net was established by David Redwood in 2000 and it was much larger than Nasstar, which paid £13m in cash and shares for the company in January and raised £10.5m from a placing at 5p a share.
Shares in Abcam (ABC), the provider of antibodies for the life sciences research and testing sector, have fallen by more than a quarter in recent weeks after a profit warning at the beginning of last month, with some investors clearly now having doubts about the long term future for the company. But new research might indicate things aren't as bad as some doomsayers believe.
Independent antibody search engine CiteAb has released new data today that suggests that this is a temporary dip for Abcam, with a brighter future ahead.